[ad_1]
DUBLIN, July 20, 2022 /PRNewswire/ — The “Bispecific Molecules in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.
Bispecific Molecules in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your bispecific drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.
Bispecific molecules carry huge treatment potential within cancer immunotherapy. In broad strokes this therapeutic category can be divided into three classes: (I) cytotoxic effector cell redirectors/CTL response; (II) tumor-targeted immunomodulators; and (II) dual immunomodulators.
Your Bispecific Molecules in Oncology: Analytical Tool covers more than 170 companies plus partners who are today developing 484 bispecific drugs where of 411 are in active development in cancer across 177 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.
Let our expertise work for you
With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected …
Full story available on Benzinga.com
[ad_2]
Source link
